NASDAQ:BFRA Biofrontera (BFRA) Stock Price, News & Analysis → Do NOT read if you believe in “woke” politics (From Stansberry Research) (Ad) Free BFRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.51▼$2.7850-Day Range$2.50▼$3.6052-Week Range$2.09▼$7.54Volume7,263 shsAverage Volume27,512 shsMarket Capitalization$73.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biofrontera alerts: Email Address Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story About Biofrontera Stock (NASDAQ:BFRA)Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Read More Ad DTIBiden’s $374B Giveaway Into This SectorBiden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full story BFRA Stock News HeadlinesMay 3, 2024 | finanznachrichten.deBiofrontera Inc.: Biofrontera Announces Achievement of Two Milestones Associated with Series B-3 Convertible Preferred Stock WarrantsMay 3, 2024 | msn.comBiofrontera files to sell 11.31M shares for holdersMay 7, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.May 1, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: Biofrontera berichtet über die Ergebnisse des Geschäftsjahres 2023April 4, 2024 | msn.comLeverkusener Pharma-AG: Warum Biofrontera sich weiter von seinem Gründer absetztApril 4, 2024 | finanznachrichten.deBiofrontera plant eine FinanzierungsrundeMarch 19, 2024 | finance.yahoo.comQ4 2023 Biofrontera Inc Earnings CallMarch 15, 2024 | investorplace.comBFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023May 7, 2024 | Colonial Metals (Ad)The Gold Grab of the CenturyWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.February 28, 2024 | morningstar.comBiofrontera Inc BFRIFebruary 20, 2024 | marketwatch.comBiofrontera Up 56% After Revised Supply Agreement, Private Placement NewsFebruary 20, 2024 | msn.comWhat's Going On With Biofrontera Stock?February 6, 2024 | msn.comBiofrontera FDA Review Advances Ameluz® Dosage ExpansionFebruary 5, 2024 | finanznachrichten.deBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz to Permit Up to Three Tubes Per UseFebruary 5, 2024 | stockhouse.comBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per UseFebruary 5, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: Ameluz® erhält Zulassungserweiterung für Anwendung mit künstlichem Tageslicht in der EU und in GroßbritannienFebruary 3, 2024 | msn.comBiofrontera’s Pre-Funded Warrants Fully Exercised by InvestorFebruary 3, 2024 | msn.comBiofrontera Amends Agreement, Adjusts Payment ScheduleFebruary 2, 2024 | msn.comWhy Is Biofrontera (BFRI) Stock Down Today?January 26, 2024 | msn.comBiofrontera Receives Extension to Regain Nasdaq ComplianceJanuary 24, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: EMA genehmigt optimierte Formulierung von Ameluz®January 11, 2024 | finanznachrichten.deBiofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023January 9, 2024 | msn.comZulassung erweitert: Wie Biofrontera auf dem europäischen Markt durchstarten willJanuary 4, 2024 | marketwatch.comBiofrontera Shares Rise on Maruho SettlementNovember 16, 2023 | morningstar.comBiofrontera AG B8FAugust 31, 2023 | finanznachrichten.dePTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN HALBJAHRES 2023August 29, 2023 | finance.yahoo.comBiofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer AccountsSee More Headlines Receive BFRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/24/2021Today5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRA CUSIPN/A CIK1712641 Webwww.biofrontera.com Phone(921) 487-6320Fax49-02-1487-6320Employees138Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net Margins-59.44% Pretax MarginN/A Return on Equity-93.31% Return on Assets-24.02% Debt Debt-to-Equity Ratio0.13 Current Ratio1.26 Quick Ratio1.13 Sales & Book Value Annual Sales$36.19 million Price / Sales2.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.43Miscellaneous Outstanding Shares28,359,000Free FloatN/AMarket Cap$73.73 million OptionableNot Optionable Beta1.02 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesLudwig LutterChief Financial OfficerPamela KeckInvestor Relations ContactKey CompetitorsJourney MedicalNASDAQ:DERMAnebulo PharmaceuticalsNASDAQ:ANEBRallybioNASDAQ:RLYBCorvus PharmaceuticalsNASDAQ:CRVSSpero TherapeuticsNASDAQ:SPROView All Competitors BFRA Stock Analysis - Frequently Asked Questions How were Biofrontera's earnings last quarter? Biofrontera AG (NASDAQ:BFRA) announced its quarterly earnings data on Wednesday, November, 24th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. The firm earned $6.34 million during the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND). When did Biofrontera IPO? Biofrontera (BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at $11.00-$13.00 per share. Benchmark acted as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. This page (NASDAQ:BFRA) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm PressThe 2024 crypto bull run has already started — don’t get left behindInvestorPlaceThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & CompanyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.